BNIP3L and Parkinson disease: This highlights Nix as a potential therapeutic target for PD, given that mitochondrial dysfunction has been identified as a key contributing factor of dopaminergic neuronal vulnerability that is present in both familial and sporadic forms of PD1, 2, 3, 32.